Using venetoclax to treat CLL patients on BTK inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, multicenter phase 2 study investigates the efficacy and safety of venetoclax as a consolidation therapy for patients with chronic lymphocytic leukemia (CLL) who have been on BTK inhibitor monotherapy for at least six months. Eligible patients will receive a combination of a BTK inhibitor and venetoclax for 12 cycles after a standard dose ramp-up. The study aims to evaluate minimal residual disease (MRD) status in peripheral blood and bone marrow during and after treatment. Following the combination therapy, patients will discontinue both medications and be monitored for outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Age: 18-80 years-old.
* 2\. Patients must have a diagnosis of CLL/SLL.
* 3\. Detectable MRD by flow cytometry (10\^-4 sensitivity) in the peripheral blood.
* 4\. Patients who are on BTK inhibitor monotherapy for more than 6 months. This study includes patients who are taking one of the following BTK inhibitors: ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib.
* 5\. Patients need to have a response of at least PR (CR/PR) to BTK inhibitor monotherapy.
* 6\. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
* 7\. Patients must have adequate renal and hepatic function:
* Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for patients with Gilbert's disease;
* Serum creatinine clearance of ≥ 50 ml/min (calculated or measured);
* ALT and AST ≤ 3.0 × ULN, unless clearly due to disease involvement.
* 8\. Adequate bone marrow function:
* Platelet count of greater than 50,000/µl, with no platelet transfusion in prior 2 weeks;
* ANC ≥ 1000/µl in the absence of growth factor support unless due to compromised bone marrow production from CLL, indicated by ≥ 80% CLL in marrow;
* Hemoglobin ≥ 8g/dL.
* 9\. Adequate cardiac function, as assessed by:
* Absence of uncontrolled cardiac arrhythmia;
* Echocardiogram demonstrating LVEF ≥ 35%;
* NYHA functional class ≤ 2.
* 10\. Ability to provide informed consent and adhere to the required follow-up.

Exclusion Criteria:

* 1\. Richter transformation.
* 2\. Active malignancy requiring systemic therapy, other than CLL, with the exception of: adequately treated in situ carcinoma of the cervix uteri; adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
* 3\. Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drug.
* 4\. Grade 3 or 4 hemorrhage within the past 3 weeks.
* 5\. Uncontrolled active infections (viral, bacterial, and fungal).
* 6\. Females who are pregnant or lactating.
* 7\. Known HIV positive.
* 8\. Active hepatitis B infection (defined as the presence of detectable HBV DNA or HBe antigen). Patients who are HBsAg positive or HBcAb positive are eligible, provided HBV DNA is negative. These patients must have monthly monitoring of HBV DNA for the duration of the study.
* 9\. Active hepatitis C, defined by the detection of hepatitis C RNA in plasma by PCR.
* 10\. Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy \> 20 mg prednisone daily or equivalent, within 7 days of starting venetoclax.
* 11\. Received other therapeutic agents for CLL/SLL during BTK inhibitor treatment prior to enrollment.
* 12\. Concurrent use of warfarin or equivalent vitamin K inhibitor or other oral anticoagulant treatment.
* 13\. Received strong CYP3A inhibitors or strong CYP3A inducers within 7 days of starting venetoclax.
* 14\. Consuming grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting venetoclax.
* 15\. Prior treatment with venetoclax or other Bcl-2 inhibitor.
* 16\. Malabsorption syndrome or other condition that precludes enteral route of administration.

Where it's running

• Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Jianyong Li, PhD, MD
• Email: lijianyonglm@126.com
• Phone: 86-13951877733

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LEF1 levels as a diagnostic and survival marker in CLL/SLL

  We will test whether measuring LEF1 protein in lymph node, bone marrow, or other tissue samples can help diagnose and predict outcomes for adults with CLL/SLL.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BOLOGNA · NCT07313982

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• Testing EXS73565 for patients with relapsed or refractory B-cell cancers

  This study is testing a new oral medication called EXS73565 to see if it can help adults with B-cell cancers that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1 Exscientia AI Limited · Tbilisi and 16 other locations · NCT06980116

• Evaluating CTX112 for B-cell malignancies

  This study is testing a new type of CAR T cell therapy called CTX112 to see if it can safely help people with tough-to-treat B-cell cancers.

  Recruiting at 7 sites Phase 1/2 CRISPR Therapeutics · Westwood, Kansas and 6 other locations · NCT05643742

• APG-3288 in relapsed/refractory blood cancers

  This study tests APG-3288 alone to see if it can be safely given and what dose works best in people whose blood cancers have returned or stopped responding to standard treatments.

  Recruiting at 5 sites Phase 1 Ascentage Pharma Group Inc. · Los Angeles, California and 5 other locations · NCT07424833

• Pirtobrutinib for Elderly CLL: See if this BTK inhibitor helps older adults

  This study tests whether pirtobrutinib can help people aged 75 and older with chronic lymphocytic leukemia that hasn’t been treated yet.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07685717

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.